Post by wei chen

52 weeks, 18.54% weight loss — a milestone for biweekly GLP-1 RA Gan & Lee announced positive topline results for bofanglutide Injection, its independently developed biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA). 📌 GRADUAL-1 Phase 3 trial (China) – met primary endpoint in adults with obesity or overweight 📌 Phase 2 trial (U.S.) – also met primary endpoint in overweight/obesity At 52 weeks, participants achieved 18.54% weight loss, reinforcing bofanglutide's potential as a differentiated, less frequent dosing option in the growing GLP-1 landscape.